All In Biotech

NDA 212535 · Baxter Hlthcare Corp

Nouress

Cysteine Hydrochloride · Intravenous

Priority review

Last checked: Nov 19, 2026Latest source record: Dec 13, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 13, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

600

111 Phase 3, 40 recruiting

FAERS reports

24

23 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 29, 2022.

Cysteine hydrochloride injection, USP is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition. Cysteine hydrochloride injection, USP is a sulfur-containing amino acid indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition. ( 1 )

Mechanism: Endogenous cysteine is synthesized from methionine by the enzyme, cystathionase, via the trans-sulfuration pathway, and serves as a precursor substrate for both glutathione and taurine. Cysteine hydrochloride injection, USP provides cysteine to the systemic circulation of neonates who require parenteral nutrition and cannot synthesize adequate quantities of cysteine due to deficient cystathionase activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 13, 2019 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
  • NOURESS · CYSTEINE HYDROCHLORIDE 500MG/10ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cysteine" as an intervention, any sponsor and status, largest first.

All 600 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hallucination6
  • pneumonia4
  • erythema multiforme3
  • malaise3
  • food craving2
  • intentional product use issue2
  • thirst2
  • accidental exposure1
  • altered state of consciousness1
  • apnoea1
  • atrial fibrillation1
  • bronchial secretion retention1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20071
20081
20101
20127
20131
20161
20173
20182
20201
20213
20232

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 965 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.